Copyright Reports & Markets. All rights reserved.

Global Hepatocellular Carcinoma Drugs Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Hepatocellular Carcinoma Drugs Market Overview

      • 1.1 Product Overview and Scope of Hepatocellular Carcinoma Drugs
      • 1.2 Hepatocellular Carcinoma Drugs Segment by Type
        • 1.2.1 Global Hepatocellular Carcinoma Drugs Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 Brachytherapy
        • 1.2.3 Chemotherapy
        • 1.2.4 Local Ablation Therapy
      • 1.3 Hepatocellular Carcinoma Drugs Segment by Application
        • 1.3.1 Hepatocellular Carcinoma Drugs Consumption Comparison by Application (2014-2025)
        • 1.3.2 Hospitals
        • 1.3.3 Clinics
        • 1.3.4 Cancer Rehabilitation Centers
      • 1.4 Global Hepatocellular Carcinoma Drugs Market by Region
        • 1.4.1 Global Hepatocellular Carcinoma Drugs Market Size Region
        • 1.4.2 North America Status and Prospect (2014-2025)
        • 1.4.3 Europe Status and Prospect (2014-2025)
        • 1.4.4 China Status and Prospect (2014-2025)
        • 1.4.5 Japan Status and Prospect (2014-2025)
      • 1.5 Global Hepatocellular Carcinoma Drugs Market Size
        • 1.5.1 Global Hepatocellular Carcinoma Drugs Revenue (2014-2025)
        • 1.5.2 Global Hepatocellular Carcinoma Drugs Production (2014-2025)

      2 Global Hepatocellular Carcinoma Drugs Market Competition by Manufacturers

      • 2.1 Global Hepatocellular Carcinoma Drugs Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Hepatocellular Carcinoma Drugs Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Hepatocellular Carcinoma Drugs Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Hepatocellular Carcinoma Drugs Production Sites, Area Served, Product Types
      • 2.5 Hepatocellular Carcinoma Drugs Market Competitive Situation and Trends
        • 2.5.1 Hepatocellular Carcinoma Drugs Market Concentration Rate
        • 2.5.2 Hepatocellular Carcinoma Drugs Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Hepatocellular Carcinoma Drugs Production Market Share by Regions

      • 3.1 Global Hepatocellular Carcinoma Drugs Production Market Share by Regions
      • 3.2 Global Hepatocellular Carcinoma Drugs Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Hepatocellular Carcinoma Drugs Production
        • 3.4.1 North America Hepatocellular Carcinoma Drugs Production Growth Rate (2014-2019)
        • 3.4.2 North America Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Hepatocellular Carcinoma Drugs Production
        • 3.5.1 Europe Hepatocellular Carcinoma Drugs Production Growth Rate (2014-2019)
        • 3.5.2 Europe Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Hepatocellular Carcinoma Drugs Production (2014-2019)
        • 3.6.1 China Hepatocellular Carcinoma Drugs Production Growth Rate (2014-2019)
        • 3.6.2 China Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Hepatocellular Carcinoma Drugs Production (2014-2019)
        • 3.7.1 Japan Hepatocellular Carcinoma Drugs Production Growth Rate (2014-2019)
        • 3.7.2 Japan Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Hepatocellular Carcinoma Drugs Consumption by Regions

      • 4.1 Global Hepatocellular Carcinoma Drugs Consumption by Regions
      • 4.2 North America Hepatocellular Carcinoma Drugs Consumption (2014-2019)
      • 4.3 Europe Hepatocellular Carcinoma Drugs Consumption (2014-2019)
      • 4.4 China Hepatocellular Carcinoma Drugs Consumption (2014-2019)
      • 4.5 Japan Hepatocellular Carcinoma Drugs Consumption (2014-2019)

      5 Global Hepatocellular Carcinoma Drugs Production, Revenue, Price Trend by Type

      • 5.1 Global Hepatocellular Carcinoma Drugs Production Market Share by Type (2014-2019)
      • 5.2 Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2014-2019)
      • 5.3 Global Hepatocellular Carcinoma Drugs Price by Type (2014-2019)
      • 5.4 Global Hepatocellular Carcinoma Drugs Production Growth by Type (2014-2019)

      6 Global Hepatocellular Carcinoma Drugs Market Analysis by Applications

      • 6.1 Global Hepatocellular Carcinoma Drugs Consumption Market Share by Application (2014-2019)
      • 6.2 Global Hepatocellular Carcinoma Drugs Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Hepatocellular Carcinoma Drugs Business

      • 7.1 Bayer
        • 7.1.1 Bayer Hepatocellular Carcinoma Drugs Production Sites and Area Served
        • 7.1.2 Hepatocellular Carcinoma Drugs Product Introduction, Application and Specification
        • 7.1.3 Bayer Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 Eli Lilly
        • 7.2.1 Eli Lilly Hepatocellular Carcinoma Drugs Production Sites and Area Served
        • 7.2.2 Hepatocellular Carcinoma Drugs Product Introduction, Application and Specification
        • 7.2.3 Eli Lilly Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 Johnson and Johnson
        • 7.3.1 Johnson and Johnson Hepatocellular Carcinoma Drugs Production Sites and Area Served
        • 7.3.2 Hepatocellular Carcinoma Drugs Product Introduction, Application and Specification
        • 7.3.3 Johnson and Johnson Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 Pfizer
        • 7.4.1 Pfizer Hepatocellular Carcinoma Drugs Production Sites and Area Served
        • 7.4.2 Hepatocellular Carcinoma Drugs Product Introduction, Application and Specification
        • 7.4.3 Pfizer Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Bristol-Myers Squibb
        • 7.5.1 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Production Sites and Area Served
        • 7.5.2 Hepatocellular Carcinoma Drugs Product Introduction, Application and Specification
        • 7.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 Celgene
        • 7.6.1 Celgene Hepatocellular Carcinoma Drugs Production Sites and Area Served
        • 7.6.2 Hepatocellular Carcinoma Drugs Product Introduction, Application and Specification
        • 7.6.3 Celgene Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 F. Hoffmann-la Roche
        • 7.7.1 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Production Sites and Area Served
        • 7.7.2 Hepatocellular Carcinoma Drugs Product Introduction, Application and Specification
        • 7.7.3 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 Gilead
        • 7.8.1 Gilead Hepatocellular Carcinoma Drugs Production Sites and Area Served
        • 7.8.2 Hepatocellular Carcinoma Drugs Product Introduction, Application and Specification
        • 7.8.3 Gilead Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served
      • 7.9 GlaxoSmithKline
        • 7.9.1 GlaxoSmithKline Hepatocellular Carcinoma Drugs Production Sites and Area Served
        • 7.9.2 Hepatocellular Carcinoma Drugs Product Introduction, Application and Specification
        • 7.9.3 GlaxoSmithKline Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.9.4 Main Business and Markets Served
      • 7.10 Merck
        • 7.10.1 Merck Hepatocellular Carcinoma Drugs Production Sites and Area Served
        • 7.10.2 Hepatocellular Carcinoma Drugs Product Introduction, Application and Specification
        • 7.10.3 Merck Hepatocellular Carcinoma Drugs Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.10.4 Main Business and Markets Served
      • 7.11 Novartis

      8 Hepatocellular Carcinoma Drugs Manufacturing Cost Analysis

      • 8.1 Hepatocellular Carcinoma Drugs Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Hepatocellular Carcinoma Drugs
      • 8.4 Hepatocellular Carcinoma Drugs Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Hepatocellular Carcinoma Drugs Distributors List
      • 9.3 Hepatocellular Carcinoma Drugs Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Hepatocellular Carcinoma Drugs Market Forecast

      • 11.1 Global Hepatocellular Carcinoma Drugs Production, Revenue Forecast
        • 11.1.1 Global Hepatocellular Carcinoma Drugs Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Hepatocellular Carcinoma Drugs Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Hepatocellular Carcinoma Drugs Price and Trend Forecast (2019-2025)
      • 11.2 Global Hepatocellular Carcinoma Drugs Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Hepatocellular Carcinoma Drugs Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Hepatocellular Carcinoma Drugs Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Hepatocellular Carcinoma Drugs Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Hepatocellular Carcinoma Drugs Production, Revenue Forecast (2019-2025)
      • 11.3 Global Hepatocellular Carcinoma Drugs Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Hepatocellular Carcinoma Drugs Consumption Forecast (2019-2025)
        • 11.3.2 Europe Hepatocellular Carcinoma Drugs Consumption Forecast (2019-2025)
        • 11.3.3 China Hepatocellular Carcinoma Drugs Consumption Forecast (2019-2025)
        • 11.3.4 Japan Hepatocellular Carcinoma Drugs Consumption Forecast (2019-2025)
      • 11.4 Global Hepatocellular Carcinoma Drugs Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Hepatocellular Carcinoma Drugs Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.
        The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.

        The global Hepatocellular Carcinoma Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Hepatocellular Carcinoma Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Hepatocellular Carcinoma Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Bayer
        Eli Lilly
        Johnson and Johnson
        Pfizer
        Bristol-Myers Squibb
        Celgene
        F. Hoffmann-la Roche
        Gilead
        GlaxoSmithKline
        Merck
        Novartis

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        Brachytherapy
        Chemotherapy
        Local Ablation Therapy

        Segment by Application
        Hospitals
        Clinics
        Cancer Rehabilitation Centers

        Buy now